Targeting an Innate Immune Signaling Pathway to Treat TNBC
Abstract
Triple negative breast cancer (TNBC) remains a challenge to clinicians, laboratory investigators, and patients due to its disproportionate number of breast cancer deaths and its lack of an established therapeutic target. Numerous studies have identified potential novel mutational gene targets in TNBC, but single-agent therapeutics have lacked substantial impact in TNBC. More recently, immune checkpoint inhibitors gained significant clinical traction in breast cancer. Unfortunately, initial promising results have been subsequently overshadowed with failures, particularly in TNBC. In other solid human tumors, the efficacy of anti-PD-L1 immune checkpoint therapies appeared to be enhanced by stimulating lymphocyte infiltration into the tumor microenvironment with type I IFNs. Here in our second year, we show induction of RIG-I and the interferon response can cause an increase in tumor infiltrating lymphocytes in animal models of TNBC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1212561
Entities
People
- Jason D Weber
Organizations
- Washington University in St. Louis